We are live on ! Find out more
COGT icon

Cogent Biosciences
COGT

135 hedge funds and large institutions have $886M invested in Cogent Biosciences in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 58 increasing their positions, 36 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

242% more call options, than puts

Call options by funds: $940K | Put options by funds: $275K

61% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 36

20.62% more ownership

Funds ownership: 85.69% → 106.31% (+21%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

1% less funds holding

Funds holding: 136 → 135 (-1)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

15% less capital invested

Capital invested by funds: $1.05B → $886M (-$162M)

Holders
135
Holders Change
-1
Holders Change %
-0.74%
% of All Funds
2.14%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
12
Increased
58
Reduced
36
Closed
13
Calls
$940K
Puts
$275K
Net Calls
+$665K
Net Calls Change
+$444K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$50.4M
2
SCM
Suvretta Capital Management
New York
+$9.89M
3
BlackRock
BlackRock
New York
+$7.94M
4
SVCM
Saturn V Capital Management
Texas
+$7.5M
5
KCM
Kynam Capital Management
New Jersey
+$7.03M

Top Sellers

1
DM
Deerfield Management
New York
-$27M
2
EAM
Eventide Asset Management
Massachusetts
-$15.3M
3
FCM
Farallon Capital Management
California
-$11.5M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$10.9M
5
LGM
Logos Global Management
California
-$9.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$62.6M – – –
BlackRock
2
BlackRock
New York
$59.9M +$7.94M +669,416 +12%
TCM
3
TCG Crossover Management
California
$54.9M – – –
CC
4
Commodore Capital
New York
$54.3M – – –
VA
5
VR Adviser
New York
$45.7M +$415 +35 +0%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$44.6M +$50.4M +4,248,521 +1,322%
Vanguard Group
7
Vanguard Group
Pennsylvania
$42.6M -$751K -63,310 -1%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$36.7M -$10.9M -918,299 -20%
FFM
9
Fairmount Funds Management
Pennsylvania
$34.7M – – –
SCM
10
Suvretta Capital Management
New York
$29.8M +$9.89M +833,607 +38%
State Street
11
State Street
Massachusetts
$28.9M -$1.9M -160,468 -5%
PA
12
Perceptive Advisors
New York
$22.5M -$4.15M -350,000 -13%
VC
13
Vivo Capital
California
$21.9M – – –
KCM
14
Kynam Capital Management
New Jersey
$21.5M +$7.03M +592,734 +37%
Marshall Wace
15
Marshall Wace
United Kingdom
$21.3M +$394K +33,211 +2%
EAM
16
Eventide Asset Management
Massachusetts
$21M -$15.3M -1,290,796 -38%
RG
17
Redmile Group
California
$20M – – –
SVCM
18
Saturn V Capital Management
Texas
$17.3M +$7.5M +632,047 +55%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$16.1M +$1.62M +136,952 +9%
Janus Henderson Group
20
Janus Henderson Group
United Kingdom
$16M +$3.78M +318,849 +24%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$15.4M +$5.48M +462,345 +41%
FLSM
22
Frazier Life Sciences Management
California
$14.6M – – –
BBA
23
Baker Bros. Advisors
New York
$12.6M +$3.72M +313,366 +32%
DM
24
Deerfield Management
New York
$10.6M -$27M -2,277,000 -68%
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
$10.1M -$1.19M -100,000 -9%
1
2 3 4 5

COGT Hedge Fund Activity: Q3 2023 in Review

135 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2023, worth a combined $886M — down 15% from $1.05B a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of COGT and 12 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 58 added.

The largest buyer was Fidelity Investments, adding an estimated $50.4M. The largest seller was Deerfield Management, cutting an estimated $27M.

  • 135 institutional investors held Cogent Biosciences (COGT) as of Q3 2023, down from 136 in Q2 2023.
  • Funds reported $886M of Cogent Biosciences stock for Q3 2023, down 15% quarter-over-quarter.
  • 12 funds opened new Cogent Biosciences positions in Q3 2023 and 13 closed out, a net change of -1 holder.
  • The largest Cogent Biosciences buyer in Q3 2023 was Fidelity Investments, an estimated $50.4M added.
  • The largest Cogent Biosciences seller in Q3 2023 was Deerfield Management, an estimated $27M sold.

Based on aggregated 13F filings for Q3 2023.